AGARWALEYEBSEDr. Agarwals Health Care LtdMediumNeutral
Announced Thu, 21 May · 18:21 IST

Presentation on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026 is attached

Investor Communications View source PDF

AGARWALEYE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.4%1-day move
₹482.00
prior close
₹487.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.4+0.2+1.1-0.4-0.6-0.5+1.0-0.4-4.4-8.8-2.5-0.0
Up moveDown movePending
AI summary

Dr. Agarwal's Health Care, India's largest eye care services chain, reported strong FY26 results with total income of ₹2,125 Cr, up 20.9% YoY. EBITDA grew 22.2% to ₹614 Cr with margins expanding to 28.9%, while PAT surged 52.4% to ₹168 Cr. The company added 57 facilities during the year (one per week), expanding to 288 total facilities across 269 in India and 19 in Africa. Same-store sales growth stood at 14.1%, with emerging facilities contributing 21.3% of revenues. The company achieved a net cash position of ₹124 Cr, improving from net debt of ₹267 Cr in FY25. Key operational metrics include 3 million+ patients served, 323,000+ surgeries performed, and 968 doctors.

Likely market impact

Strong operational and financial performance with margin expansion and cash generation indicates healthy business execution. The rapid facility expansion and solid same-store growth suggest continued market share gains in the fragmented eye care market.